Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype

Molecular and Cellular Endocrinology

Volumn 264, Issue 1-2, 2007, Pages 44-49

  Graziani, Grazia ^a   Tentori, Lucio ^a   Muzi, Alessia ^a   Vergati, Matteo ^a   Tringali, Giuseppe ^b   Pozzoli, Giacomo ^b   Navarra, Pierluigi ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antalarmin; Astressin; Breast cancer; CRH; CRH R1 receptor subtype; Estradiol; MCF7 cells

Indexed keywords

ANTALARMIN; ASTRESSIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; ESTRADIOL; ESTROGEN; HORMONE RECEPTOR BLOCKING AGENT; MESSENGER RNA; RIBONUCLEASE;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RIBONUCLEASE PROTECTION ASSAY; TUMOR CELL LINE;

AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HORMONES; HUMANS; PARACRINE COMMUNICATION; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 33846216433     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2006.10.006     Document Type: Article

References (18)

1. Bale T.L., Giordano F.J., Hickey R.P., Huang Y., Nath A.K., Peterson K.L., Vale W.W., and Lee K.F. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7734-7739
2. Behan D.P., De Souza E.B., Lowry P.J., Potter E., Sawchenko P., and Vale W.W. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front. Neuroendocrinol. 16 (1995) 362-382
3. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
4. Ciocca D.R., Puy L.A., Fasoli L.C., Tello O., Aznar J.C., Gago F.E., Papa S.I., and Sonego R. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res. Treat. 15 (1990) 175-178
5. Cunnah D., Jessop D.S., Besser G.M., and Rees L.H. Measurement of circulating corticotrophin-releasing factor in man. J. Endocrinol. 113 (1987) 123-131
6. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., and Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 97 (2005) 1407-1427
7. Florio P., Rossi M., Sigurdardottir M., Ciarmela P., Luisi S., Vigano P., Grasso D., Fiore G., Cobellis L., Di Blasio A.M., and Petraglia F. Paracrine regulation of endometrial function: interaction between progesterone and corticotropin-releasing factor (CRF) and activin A. Steroids 68 (2003) 801-807
8. Graziani G., Tentori L., Portarena I., Barbarino M., Tringali G., Pozzoli G., and Navarra P. CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143 (2002) 807-813
9. Graziani G., Ferrandina G., Pozzoli G., Vergati M., Muzi A., Legge F., Tentori L., Scambia G., and Navarra P. Corticotrophin-releasing hormone receptor-1 in human endometrial cancer. Oncol. Rep. 15 (2006) 375-379
10. Gulyas J., Rivier C., Perrin M., Koerber S.C., Sutton S., Corrigan A., Lahrichi S.L., Craig A.G., Vale W., and Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10575-10579
11. Linton E.A., McLean C., Nieuwenhuyzen Kruseman A.C., Tilders F.J., Van der Veen E.A., and Lowry P.J. Direct measurement of human plasma corticotropin-releasing hormone by "two-site" immunoradiometric assay. J. Clin. Endocrinol. Metab. 64 (1987) 1047-1053
12. Navarra P., Tsagarakis S., Faria M.S., Rees L.H., Besser G.M., and Grossman A.B. Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 128 (1991) 37-44
13. Parham K.L., Zervou S., Karteris E., Catalano R.D., Old R.W., and Hillhouse E.W. Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology 145 (2004) 3971-3983
14. Petraglia F., Potter E., Cameron V.A., Sutton S., Behan D.P., Woods R.J., Sawchenko P.E., Lowry P.J., and Vale W. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J. Clin. Endocrinol. Metab. 77 (1993) 919-924
15. Pozzoli G., Bilezikjian L.M., Perrin M.H., Blount A.L., and Vale W.W. Corticotropin-releasing factor (CRF) and glucocorticoids modulate the expression of type 1 CRF receptor messenger ribonucleic acid in rat anterior pituitary cell cultures. Endocrinology 137 (1996) 65-71
16. Pozzoli G., Tringali G., Vairano M., D'Amico M., Navarra P., and Martire M. Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression. J. Neurosci. Res. 83 (2006) 1058-1065
17. Reubi J.C., Waser B., Vale W., and Rivier J. Expression of CRF1 and CRF2 receptors in human cancers. J. Clin. Endocrinol. Metab. 88 (2003) 3312-3320
18. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., and Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137 (1996) 5747-5750